Akero Therapeutics, Inc. (AKRO) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en South San Francisco, CA, United States. El CEO actual es Andrew Cheng.
AKRO tiene fecha de IPO 2019-06-20, 69 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $4.5B.
Akero Therapeutics, Inc. is a cardio-metabolic company focused on developing treatments for nonalcoholic steatohepatitis (NASH) and related metabolic disorders. The company's lead product candidate is efruxifermin (EFX), a fibroblast growth factor 21 analog designed to restore metabolic balance by protecting against cellular stress and regulating the metabolism of lipids, carbohydrates, and proteins throughout the body. Akero is advancing efruxifermin through clinical development, including the Phase 2a BALANCED study evaluating its efficacy in biopsy-confirmed NASH patients. Headquartered in South San Francisco, California, the company was founded in 2017 and rebranded from its former name, Pippin Pharmaceuticals, Inc., in May 2018.
